ABSTRACT
OBJECTIVE: The aim of this study was to compare Biatain Ag and Biatain Alginate Ag (both Coloplast, Denmark) as skin graft donor site dressings. METHOD: A single-centre, prospective, randomised clinical study was conducted. In patients who had undergone a skin graft operation, adjacent split-thickness skin graft donor sites were dressed with Biatain Ag and Biatain Alginate Ag, respectively. The primary outcomes were time to re-epithelialisation and pain score after the operation. The secondary outcomes were scar scores of the donor site after the operation, haematoma rates, infection rates, and exudation rates before wound healing. Results were compared using the Wilcoxon test and the Chi-squared test. RESULTS: A total of 16 paired wounds in 16 patients were studied. The donor sites dressed with Biatain Ag needed more time for >90% re-epithelialisation than those dressed with Biatain Alginate Ag. On day 3 postoperatively, the pain scores with Biatain Ag were significantly less severe than those with Biatain Alginate Ag. On days 6, 9 and 12, the pain scores of both dressings did not differ significantly. The scar scores of the donor site dressed with Biatain Ag were significantly worse than those dressed with Biatain Alginate Ag at 6 months. With respect to infection rates, no significant differences were detected between these two groups. However, the exudation rates of the donor site dressed with Biatain Ag were significantly lower than those dressed with Biatain Alginate Ag. CONCLUSION: As skin graft donor site dressings, both Biatain Ag and Biatain Alginate Ag have advantages.
Subject(s)
Cicatrix , Skin Transplantation , Humans , Prospective Studies , Bandages , Alginates/therapeutic use , PainABSTRACT
Objective:To systematically evaluate the effects of body mass index (BMI) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).Methods:The databases (PubMed, Medline,Web of Science) were searched to identify clinical literatures about the relationship between BMI and the prognosis of DLBCL according to the inclusion and exclusion criteria. RevMan 5.3 software was used to analyze hazard ratio ( HR) and 95% confidence interval (95% CI) of overall survival (OS) and progression-free survival (PFS); the quality of included literatures, publication bias risk and heterogeneity were also evaluated. Results:There were 12 articles included in our research. Meta-analysis result showed that compared with normal weight patients (BMI 18.5-24.9 kg/m 2), the overweight patients (BMI 25.0-29.9 kg/m 2) had longer OS and PFS time, while the differences were not statistically significant (OS: HR=0.93, 95% CI 0.78-1.11, P=0.42; PFS: HR=0.89, 95% CI 0.67-1.20, P=0.45). The under-weight (BMI < 18.5 kg/m 2) (OS: HR=1.97, 95% CI 1.41-2.74, P < 0.01; PFS: HR=1.89, 95% CI 1.19-3.03, P < 0.01) and the obesity (BMI≥30.0 kg/m 2) patients both had shorter OS and PFS time, but the latter had no statistically significant difference (OS: HR=1.15, 95% CI 0.88-1.51, P=0.31; PFS: HR=1.32, 95% CI 0.90-1.94, P=0.15). No publication bias was observed in the symmetric funnel plot analysis. Conclusion:The increased BMI within a certain range is a protective factor for the prognosis of DLBCL patients.
